Head-To-Head Survey: Perspective Therapeutics (NYSE:CATX) & UFP Technologies (NASDAQ:UFPT)

UFP Technologies (NASDAQ:UFPT) and Perspective Therapeutics (NYSE:CATX) are both industrial products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares UFP Technologies and Perspective Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
UFP Technologies	11.74%	18.92%	12.33%
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for UFP Technologies and Perspective Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UFP Technologies	0	1	2	0	2.67
Perspective Therapeutics	0	1	8	0	2.89

UFP Technologies presently has a consensus target price of $323.50, indicating a potential upside of 4.04%. Perspective Therapeutics has a consensus target price of $15.14, indicating a potential upside of 246.52%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Perspective Therapeutics is more favorable than UFP Technologies.

Institutional and Insider Ownership

87.3% of UFP Technologies shares are owned by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are owned by institutional investors. 6.2% of UFP Technologies shares are owned by company insiders. Comparatively, 3.5% of Perspective Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares UFP Technologies and Perspective Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UFP Technologies	$461.85 million	5.17	$44.92 million	$7.01	44.36
Perspective Therapeutics	$1.43 million	206.55	-$46.51 million	N/A	N/A

UFP Technologies has higher revenue and earnings than Perspective Therapeutics.

Volatility & Risk

UFP Technologies has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.

Summary

UFP Technologies beats Perspective Therapeutics on 7 of the 12 factors compared between the two stocks.

About UFP Technologies

UFP Technologies, Inc. designs and manufactures solutions for medical devices, sterile packaging, and other highly engineered custom products. The company offers protective drapes for robotic surgery, single patient use surfaces, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices, orthopedic implants, biopharma drug manufacturing, and coils for catheters; and molded components for applications in acoustic insulation, interior trim, load floors, sunshades, SUV cargo cover handles, driveshaft damping, engine and manifold covers, quarter panels, and wheel liners. It also provides molded composites for commercial aviation and military gear for use in backpack components, knee and elbow pads, eyewear, and helmets; and reusable cases and custom for applications in military ballistics panels, virtual training systems, drones, communications equipment, and rugged portable computers. In addition, the company provides engineered products and components to customers in the automotive, aerospace and defense, and industrial markets for applications in military uniform and gear components, automotive interior trim, air filtration, and protective cases and inserts. It markets and sells its products through a direct sales force. The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.